title: Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers.
abstract: Objection: The aim of this study is to investigate the association between promoter methylation of RASSF1A and p16 and the clinicopathological features in lung cancers.
  
  
  METHODS
  PubMed, EBSCO, Ovid, Wiley, Web of Science, Wanfang, and VIP databases were searched using combinations of keywords related to RASSF1A, p16, methylation, and lung cancers. After screening for relevant studies, following a strict inclusion and exclusion criteria; the selected studies were incorporated into the present meta.analysis conducted using Comprehensive Meta Analysis 2.0. (CMA 2.0).
  
  
  RESULTS
  We initially retrieved 402 studies, out which 13 studies met the inclusion and exclusion criteria for this meta.analysis, and contained a total of 1,259. patients with lung cancers. The results of this meta.analysis showed that the differences in promoter methylation ratio between the lung cancer patients in tumor, node, metastasis. (TNM) I.II and III.IV were not statistically significant. Based on histological types, patients with adenocarcinoma. (AC) and squamous cell carcinoma. (SCC) showed no significant differences in the promoter methylation ratios of RASSF1A, while the promoter methylation ratio of p16 was significantly higher in SCC patients compared to AC patients. Based on smoking status, the promoter methylation ratios of both RASSF1A and p16 was significantly higher in lung cancer patients with smoking history compared to nonsmokers.
  
  
  CONCLUSIONS
  The present meta.analysis provides convincing evidence that the promoter methylation ratio of RASSF1A and p16 is associated with clinicopathological features in lung cancers, and could be used as effective biomarkers in early diagnosis in lung cancers.
authors.forename: Ji-Chang
authors.initials: JC
authors.lastname: Han
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.forename: Na
authors.initials: N
authors.lastname: Chen
authors.forename: Guan-Bin
authors.initials: GB
authors.lastname: Qi
authors.forename: Yu-Ju
authors.initials: YJ
authors.lastname: Wei
authors.forename: Hong-Bing
authors.initials: HB
authors.lastname: Li
authors.affiliation: Department of Respiration, Huaihe Hospital of Henan University, Kaifeng, People's Republic of China.
authors.forename: Yi-Jie
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Jing-He
authors.initials: JH
authors.lastname: Li
authors.forename: Xiu-Li
authors.initials: XL
authors.lastname: Wang
authors.forename: Wen
authors.initials: W
authors.lastname: Xu
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Li
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Jin
authors.forename: Jiao-Yuan
authors.initials: JY
authors.lastname: Jia
authors.forename: Zhong-Sen
authors.initials: ZS
authors.lastname: Ma
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019175:DNA Methylation / Q000235:genetics; D055088:Early Detection of Cancer; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D011401:Promoter Regions, Genetic; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; C411762:RASSF1 protein, human; D025521:Tumor Suppressor Proteins